Clinical observation and the influence of serum VEGF level by Lobaplatin combined with Aidi Injection for the treatment of malignant pleural effusion
10.3969/j.issn.1006-5725.2014.10.038
- VernacularTitle:洛铂胸腔灌注联合艾迪注射液治疗恶性胸腔积液的临床分析及其对血清VEGF的影响
- Author:
Yang ZHOU
;
He HUANG
;
Jiahong ZHANG
- Publication Type:Journal Article
- Keywords:
Malignant pleural effusion;
Lobaplatin;
Aidi Injection;
VEGF
- From:
The Journal of Practical Medicine
2014;(10):1629-1631,1632
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the treatment effect of Lobaplatin combined with Aidi Injection on patients with advanced NSCLC, and observe the influence on the level of serum VEGF by the treatment. Methods 60 patients, with advanced NSCLC and malignant pleural effusion, were divided into two groups (observation group and control group) randomly, with 30 cases in each group. All patients were treated with thoracentesis and inserted central venous catheter for the drainage of pleural effusion. After exhaustion of pleural effusion, the control group was treated with Lobaplatin by pleural perfusion, and the observation group was treated with Aidi Injection in addition to the treatment on control group. The treatment, side effects and quality of life and the level of serum VEGF were compared. Results After treatment, it is significant that clinical effects, side effect and KPS score of living quality of the observation group was better than that of the control group (P<0.05). The level of serum VEGF was significant lower than that before treatment in both groups (P<0.05). The decrease of VEGF serum level in the observation group was significantly lower than the decrease in the control group (P <0.05). Conclusion Lobaplatin combined with Aidi Injection was one of the effective method for the treatment of NSCLS with malignant pleural effusion, and was worthy of clinical application.
